Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes

Breast cancer commonly metastasises to the brain, but little is known about changes in the molecular profile of the brain secondaries and impact on clinical outcomes. Patients with samples from brain metastases and matched breast cancers were included. Immunohistochemical analysis for oestrogen rece...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2016-03, Vol.114 (7), p.793-800
Main Authors: Thomson, A H, McGrane, J, Mathew, J, Palmer, J, Hilton, D A, Purvis, G, Jenkins, R
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - metabolism
Brain Neoplasms - metabolism
Brain Neoplasms - mortality
Brain Neoplasms - secondary
Breast Neoplasms - metabolism
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Female
Follow-Up Studies
Humans
Immunoenzyme Techniques
In Situ Hybridization, Fluorescence
Middle Aged
Molecular Diagnostics
Neoplasm Staging
Prognosis
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer commonly metastasises to the brain, but little is known about changes in the molecular profile of the brain secondaries and impact on clinical outcomes. Patients with samples from brain metastases and matched breast cancers were included. Immunohistochemical analysis for oestrogen receptor, progesterone receptor, p27kip1, cyclin D1, epidermal growth factor receptor, insulin like growth factor 1, insulin like growth factor 1 receptor, vascular endothelial growth factor A, transforming growth factor-β and HER2 receptor was performed. Borderline HER2 results were analysed by fluorescent in situ hybridisation. Levels of expression were compared, with review of effect on clinical outcomes. A total of 41 patients were included. Of the patients, 20% had a change in oestrogen receptor or HER2 in their brain metastasis that could affect therapeutic decisions. There were statistically significant rises in brain metastases for p27kip1 (P=0.023) and cyclin D1 (P=0.030) and a fall in vascular endothelial growth factor A (P=0.012). Overall survival from the time of metastasis increased significantly with oestrogen receptor-positive (P=0.005) and progesterone receptor-positive (P=0.013) brain lesions and with a longer duration from diagnosis of the breast primary (P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2016.34